Inactivating mutations of LZTR1 have also been associated with drug resistance in RAS-induced chronic myeloid leukemia (Bigenzahn et al., 2018), whereas another class of both loss of function and dominantly acting LZTR1 mutations seems to predispose to the development of glioblastoma and adult-onset schwannomatosis (a rare cancer-prone disorder) (Piotrowski et al., 2014; Paganini et al., 2015; Motta et al., 2019). The gene discussed is LZTR1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.